Brief Summary
The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.
Intervention / Treatment
- Drug: Sonrotoclax
- Drug: Zanubrutinib
Inclusion Criteria:
- Stable ECOG Performance Status ≤ 2.
- Adequate organ function and no very recent transfusion or bloodthe red bodily fluid that transports oxygen and other nutrients around the body growth factor
- Participants of childbearing potential must be willing to use a highly effective method of birth control and refrain from egg donation for the duration of the study and for ≥ 90 days after the last dosethe amount of medication taken of sonrotoclax or ≥ 30 days after the last dose of zanubrutinib, whichever is later.
- Confirmed diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of CLL, based on Hallek et al 2018, and requiring treatment due to certain features of their disease
- At least 1 measurable lesion based on computed tomography (CT)/magnetic resonance imagingtests that create detailed images of areas inside the body (MRI) and no history of prolymphocytic leukemia or Richter’s transformation.